Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

CLK-1 inhibition may explain the effect of clioquinol in neurodegenerative diseases

Jan. 28, 2009

EpiCept reports positive results from phase IIb EpiCept trial

Jan. 28, 2009

MAP completes patient enrollment in phase III clinical trial of MAP-0004

Jan. 27, 2009

Glenmark files phase I trial application with MHPRA for GRC-15300

Jan. 26, 2009

FDA approves Geron's IND for phase I clinical trial of GRNOPC-1 in spinal cord injury

Jan. 26, 2009

Cladribine significantly reduced relapse rate of MS in phase III pivotal trial

Jan. 26, 2009

Fenobam safe, affects behavior in patients with Fragile X syndrome

Jan. 26, 2009

Solvay claims novel cannabinoid CB1 receptor agonists for use as analgesic agents

Jan. 26, 2009

Novartis launches Extavia for multiple sclerosis

Jan. 23, 2009

Phase III data support use of NGX-4010 in postherpetic neuralgia

Jan. 23, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...